Y-Intercept (HK)’s IDEAYA Biosciences IDYA Stock Holding History

Y-Intercept (HK)’s Portfolio IDYA Stock Details IDYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-54,618	Closed	-$1.82M	–	1922
2026 Q1	$1.82M	Sell	54,618 -26,415	-33%	-$886K	0.03%	759
2025 Q4	$2.8M	Buy	+81,033	New	+$2.58M	0.06%	455
2024 Q1	–	Sell	-14,218	Closed	-$506K	–	1548
2023 Q4	$506K	Buy	+14,218	New	+$424K	0.05%	599

Other funds holding IDYA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Y-Intercept (HK)'s IDYA Position: Q2 2026 in Review

Y-Intercept (HK) sold out of IDEAYA Biosciences (IDYA) in Q2 2026, closing a stake of 54,618 shares — an estimated $1.82M sold.

Y-Intercept (HK) first reported a position in IDYA in Q4 2023 and held it in 3 quarters. The position peaked at $2.8M in Q4 2025. 286 funds tracked by Wall St. Rank hold IDYA as of Q2 2026.

Y-Intercept (HK) reported no remaining IDEAYA Biosciences position as of Q2 2026 after selling out during the quarter.
Y-Intercept (HK) sold 54,618 IDEAYA Biosciences shares in Q2 2026, an estimated $1.82M.
Y-Intercept (HK) first reported a position in IDEAYA Biosciences in Q4 2023 and held it in 3 quarters.
Y-Intercept (HK)'s IDEAYA Biosciences position peaked at $2.8M in Q4 2025.
286 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.